The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Mirolyubova O.A.

Northern State Medical University, Arkhangelsk, Russia

Strelkova A.V.

Northern State Medical University, Arkhangelsk, Russia

Moseeva A.S.

Northern State Medical University, Arkhangelsk, Russia

Sibirtseva V.V.

Northern State Medical University, Arkhangelsk, Russia

Mitkin N.A.

Northern State Medical University, Arkhangelsk, Russia

Kudryavtsev A.V.

Northern State Medical University, Arkhangelsk, Russia

Evaluation of the predictive ability of cystatin C and soluble Fas-receptor for the ischemic events development using a population-based biobank

Authors:

Mirolyubova O.A., Strelkova A.V., Moseeva A.S., Sibirtseva V.V., Mitkin N.A., Kudryavtsev A.V.

More about the authors

Journal: Russian Journal of Preventive Medicine. 2026;29(3): 78‑85

DOI: 10.17116/profmed20262903178

Read: 443 times

Contact the author
Table of contents

EVALUATION OF THE PREDICTIVE ABILITY OF CYSTATIN C AND SOLUBLE FAS-RECEPTOR FOR THE ISCHEMIC EVENTS DEVELOPMENT USING A POPULATION-BASED BIOBANK
EVALUATION OF THE PREDICTIVE ABILITY OF CYSTATIN C AND SOLUBLE FAS-RECEPTOR FOR THE ISCHEMIC EVENTS DEVELOPMENT USING A POPULATION-BASED BIOBANK

To cite this article:

Mirolyubova OA, Strelkova AV, Moseeva AS, Sibirtseva VV, Mitkin NA, Kudryavtsev AV. Evaluation of the predictive ability of cystatin C and soluble Fas-receptor for the ischemic events development using a population-based biobank. Russian Journal of Preventive Medicine. 2026;29(3):78‑85. (In Russ.)
https://doi.org/10.17116/profmed20262903178

 
Подписка 2026 Профилактическая медицина (Russian Journal of Preventive Medicine)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Sarcopenia index for dete­cting of the decreased muscle stre­ngth and mass in patients with the non-alcoholic fatty liver disease. Russian Journal of Preventive Medi­cine. 2025;(7):68-74
Evaluation of the renal function patients with early carbohydrate meta­bolism diso­rders and arte­rial hype­rtension in the primary healthcare. Russian Journal of Preventive Medi­cine. 2025;(12):35-42
Rela­tionship between kidney-related brain dysfunction and neuropathological changes in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2026;(3):30-37
Pathomorphosis of transplanted C6 glioma treated with a 1267 nm wave­length laser. Russian Journal of Archive of Pathology. 2026;(2):52-58
Abstract:

Identification of individuals at high risk of atherosclerotic cardiovascular disease and premature death is essential for the development of primary prevention strategies.

OBJECTIVE

To evaluate the predictive value of cystatin C and soluble Fas receptor for ischemic events in the 35—69-year-old population.

MATERIALS AND METHODS

Data from the cross-sectional study «Know Your Heart» (Arkhangelsk, Russia), performed in 2015—2017 (n=2370), the participants’ biomaterials bank, and prospective observation (median 7.5 years, n=2232) were used. Thirty-six endpoint cases (non-fatal myocardial infarction and death from coronary artery disease through September 2024) and 124 non-event controls were analyzed. Multivariate logistic regression analysis, adjusted for age, sex, and biomarker levels, was used.

RESULTS

High cystatin C (Q4) levels were associated with endpoint (ORa=5.29; 95% CI 1.48-18.93; p=0.010). However, when N-terminal brain natriuretic propeptide (N-t proBNP) (ln) and high-sensitivity C-reactive protein (hsCRP) (ln) were added to the model, this association lost statistical significance (ORa=3.30; 95%CI 0.87—12.47; p=0.079). In a case-control analysis, incorporation of the Fas receptor for apoptosis (sFas) to the model with two predictors (N-t proBNP, hsCRP) improved prediction value (ORa=4.19; 95% CI 1.05—16.76; p=0.042); comparison of the models (p=0.0415). The combination of sFas(ln), N-t proBNP(ln), and hsCRP(ln) demonstrated superior predictive value compared to cystatin C alone.

CONCLUSION

Both immune-regulation biomarkers of apoptosis (cystatin C and soluble Fas receptor) have predictive value for adverse ischemic events, with soluble Fas receptor demonstrating independent predictive value in multivariate models.

Keywords:

cystatin C
apoptosis
soluble Fas receptor
predictive value
ischemic event

Authors:

Mirolyubova O.A.

Northern State Medical University, Arkhangelsk, Russia

Strelkova A.V.

Northern State Medical University, Arkhangelsk, Russia

Moseeva A.S.

Northern State Medical University, Arkhangelsk, Russia

Sibirtseva V.V.

Northern State Medical University, Arkhangelsk, Russia

Mitkin N.A.

Northern State Medical University, Arkhangelsk, Russia

Kudryavtsev A.V.

Northern State Medical University, Arkhangelsk, Russia

Received:

08.11.2025

Accepted:

10.12.2025

Close metadata

References:

  1. Neumann JT, Twerenbold R, Weimann J et al. Prognostic value of cardiovascular biomarkers in the population. JAMA. 2024;331(22):1898-1909. https://doi.org/10.1001/jama.2024.5596
  2. Mitkin NA, Brenn B, Unguryanu TN et al. Alcohol and cause-specific mortality in Russia: the Know Your Heart Study 2015—23. BMC Public Health. 2024;24:3128. https://doi.org/10.1186/s12889-024-20674-8
  3. Lee T-S, Chau L-Y. Fas/Fas ligand-mediated death pathway is involved in oxLDL-induced apoptosis in vascular smooth muscle cells. American Journal of Physiology — Cell Physiology. 2001;280(3):709-718.  https://doi.org/10.1152/ajpcell.2001.280.3.C709
  4. Kayukov IG, Smirnov AV, Emanuel VL. Cystatin C in current medicine. Nephrology. 2012;16(1):22-39. (In Russ.).
  5. Moiseev VC, Mukhin NA, Smirnov AV et al. Cardiovascular risk and chronic kidney disease: cardio-nephroprotection strategies. Rossijskij kardiologicheskij zhurnal. 2014;(8):7-37. (In Russ.). https://doi.org/10.15829/1560-4071-2014-8-7-37
  6. Zi M, Xu Y. Involvement of cystatin C in immunitiy and apoptosis. Immunology Letters. 2018;196:80-90.  https://doi.org/10.1016/j.imlet.2018.01.006
  7. Chen Z, Zhang J, Feng J et al. Higher serum level of Cystatin C: An additional risk factor of CAD. Medicine. 2021;100:2.  https://doi.org/10.1097/MD.0000000000024269
  8. Lagunas-Rangel FA. Fas (CD95)/FasL (CD178) system during ageing. Cell Biology International. 2023;47:1295-1313. https://doi.org/10.1002/cbin.12032
  9. Cook S, Malyutina S, Kudryavtsev AV et al. Know Your Heart: Rationale, design and conduct of a cross-sectional study of cardiovascular structure, function and risk factors in 4500 men and women aged 35-69 years from two Russian cities, 2015-18. Wellcome Open Research. 2018;3:67.  https://doi.org/10.12688/wellcomeopenres.14619.3
  10. Iyngkaran P. Old, the new, more or less and the conundrum for biomarkers in cardiovascular diseases? World Journal of Clinical Cases. 2024;12(28):6244-6246. https://doi.org/10.12998/wjcc.v12.i28.6244
  11. Gusakova AM, Kravchenko ES, Suslova TE et al. Biobanks in cardiovascular disease research. Cardiovascular Therapy and Prevention. 2024;23(11):4170. (In Russ.). https://doi.org/10.15829/1728-8800-2024-4170
  12. Garcia-Carretero R, Vigil-Medina L, Barquero-Perez O et al. Cystatin C as a predictor of cardiovascular outcomes in a hypertensive population. Journal of Human Hypertension. 2017;31(12):801-807.  https://doi.org/10.1038/jhh.2017.68
  13. Luo J, Wang L-P, Hu H-F et al. Cystatin C and cardiovascular or all-cause mortality risk in the general population: a meta-analysis. Clinica Chimica Acta. 2015;450:39-45.  https://doi.org/10.1016/j.cca.2015.07.016
  14. Pruc M, Swieczkowski D, Cander B et al. Diagnostic and prognostic value of cystatin C in acute coronary syndrome: An up-to-date meta-analysis. Cardiology Journal. 2025;32(2):142-152.  https://doi.org/10.5603/cj.102453
  15. Chen J, Shen J, Pan Y et al. Association of serum cystatin C level with coronary atherosclerotic plaque burden: a comprehensive analysis of observational studies and genetic study. BMC Cardiovascular Disorders. 2023;10; 23(1):499.  https://doi.org/10.1186/s12872-023-03506-2
  16. Luc G, Bard JM, Lesueur C et al. Plasma cystatin-C and development of coronary heart disease: The PRIME Study. Atherosclerosis. 2006;185(2):375-380.  https://doi.org/10.1016/j.atherosclerosis.2005.06.017
  17. Ekerblom A, Wallentin L, Siegbahn A et al. Cystatin C and estimated glomerular filtration rate as predictors for adverse outcome in patients with ST-elevation and non-ST-elevation acute coronary syndromes: results from the platelet inhibition and patient outcomes study. Clinical Chemistry. 2012; 58:190-199.  https://doi.org/10.1373/clinchem.2011.171520
  18. Köttgen A, Selvin E, Stevens LA et al. Serum cystatin C in the United States: The Third National Health and Nutrition Examination Survey (NHANES III). American Journal of Kidney Diseases. 2008;51(3):385-394.  https://doi.org/10.1053/j.ajkd.2007.11.019
  19. He M, Ke PF, Chen WY et al. Clinical correlates and reference intervals for cystatin C in a Han population from Southeast China. Clinical Laboratory. 2017;63(3):607-615.  https://doi.org/10.7754/Clin.Lab.2016.160807
  20. Alshammary AF, Alharbi KK, Alshehri NJ et al. Metabolic syndrome and coronary artery disease risk: a meta-analysis of observational studies. International Journal of Environmental Research and Public Health. 2021;18(4):1773. https://doi.org/10.3390/ijerph18041773
  21. Servais A. Giral P, Bernard M et al. Is serum cystatin-C a reliable marker for metabolic syndrome? American Journal of Medicine. 2008;121(5):426-432.  https://doi.org/10.1016/j.amjmed.2008.01.040
  22. Vigil L, Lopez M, Condés E et al. Cystatin C is associated with the metabolic syndrome and other cardiovascular risk factors in a hypertensive population. Journal of the American Society of Hypertension. 2009;3(3):201-209.  https://doi.org/10.1016/j.jash.2009.01.002
  23. Mao Q, Zhao N, Wang Y et al. Association of Cystatin C with Metabolic Syndrome and Its Prognostic Performance in Non-ST-Segment Elevation Acute Coronary Syndrome with Preserved Renal Function. BioMed Research International. 2019:8541402. https://doi.org/10.1155/2019/8541402
  24. Qing X, Furong W, Yunxia L et al. Cystatin C and asymptomatic coronary artery disease in patients with metabolic syndrome and normal glomerular filtration rate. Cardiovascular Diabetology. 2012;11:108.  https://doi.org/10.1186/1475-2840-11-108
  25. Kraler S, Mueller C, Libby P et al. Acute coronary syndromes: mechanisms, challenges, and new opportunities. European Heart Journal. 2025;46:2866-2889. https://doi.org/10.1093/eurheartj/ehaf289
  26. Antonopoulos AS, Angelopoulos A, Papanikolaou P et al. Biomarkers of Vascular Inflammation for Cardiovascular Risk Prognostication A Meta-Analysis. JACC. Cardiovascular Imaging. 2022;15:460-471.  https://doi.org/10.1016/j.jcmg.2021.09.014
  27. Occhipinti G, Brugaletta S, Abbate A et al. Inflammation in coronary atherosclerosis: diagnosis and treatment. Heart. 2025;0:1-10.  https://doi.org/10.1136/heartjnl-2024-325408
  28. Nubila AD, Dilella G, Simone R et al. Vascular Extracellular Matrix in Atherosclerosis. International Journal of Molecular Sciences. 2024;25(22): 1201-1207. https://doi.org/10.3390/ijms252212017
  29. Shlipak MG, Katz R, Cushman M et al. Cystatin-C and inflammatory markers in the ambulatory elderly. American Journal of Medicine. 2005;18:1416.e25-1416.e31.  https://doi.org/10.1016/j.amjmed.2005.07.060
  30. Knight EI, Verhave JC, Spiegelman D et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney International. 2004;65(4):1416-1421. https://doi.org/10.1111/j.1523-1755.2004.00517.x
  31. Shimizu M, Fukuo K, Nagata S et al. Increased plasma levels of the soluble form of Fas ligand in patients with acute myocardial infarction and unstable angina pectoris. Journal of the American College of Cardiology. 2002; 39(4): 585-590.  https://doi.org/10.1016/s0735-1097(01)01800-9
  32. Teringova E, Tousek P. Apoptosis in ischemic heart disease. Journal of Translational Medicine. 2017;15:87.  https://doi.org/10.1186/s12967-017-1191-y
  33. Yakovleva AS, Mirolyubova OA. Clinical and laboratory associations of Fas-dependent apoptosis in patients with acute and chronic coronary heart disease. Ateroskleroz. 2013;9(2):20-28. (In Russ.).
  34. Berezikova E, Pustovetova M, Shilov S et al. The influence of apoptosis on the course of chronic heart failure. Patologiya krovoobrashheniya i kardioxirurgiya. 2012;16(4):55-58. (In Russ.).
  35. Choi JW, Kim SK. Relationships of Soluble APO-1 (Fas/CD95) Concentrations, Obesity, and Serum Lipid Parameters in Healthy Adults. Annals of Clinical and Laboratory Science. 2005;35(3):290-296. 
  36. Morze J, Melloni GEM, Wittenbecher C et al. ApoB-containing lipoproteins: count, type, size, and risk of coronary artery disease. European Heart Journal. 2025;46:2691-2701. https://doi.org/10.1093/eurheartj/ehaf207
  37. Huo J, Xu S, Lam KP. FAIM: an antagonist of Fas-killing and beyond. Cells. 2019;8(6):541.  https://doi.org/10.3390/cells8060541
  38. Liu X, Hu D, Zeng Z et al. SRT1720 promotes survival of aged human mesenchymal stem cells via FAIM: a pharmacological strategy to improve stem cell-based therapy for rat myocardial infarction. Cell Death and Disease. 2017;8:e2731. https://doi.org/10.1038/cddis.2017.107
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.